Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Cancer

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2014.12.005PMID 25559615
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Author response: Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2015cited by this paper
• 2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

  2015cited by this paper
• SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

  2015cited by this paper
• Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).

  2014cited by this paper
• LBA17RANDOMISED STUDY OF AXITINIB (AXI) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO (PBO) PLUS BSC IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING PRIOR ANTIANGIOGENIC THERAPY

  2014cited by this paper
• Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.

  2014cited by this paper
• A phase 2 study of a novel transforming growth factor-beta (TGF-{beta}1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC).

  2014cited by this paper
• Exomics and immunogenics

  2014cited by this paper
• EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.

  2014cited by this paper
• A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

  2014cited by this paper
• Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design

  2014cited by this paper
• Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168).

  2014cited by this paper
• Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).

  2014cited by this paper
• A phase II study of temsirolimus in previously treated advanced hepatocellular carcinoma (HCC).

  2014cited by this paper
• Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics, and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.

  2014cited by this paper
• Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification

  2014cited by this paper
• Precision cancer medicine: the future is now, only better.

  2014cited by this paper
• Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).

  2014cited by this paper
• Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies

  2014cited by this paper
• 1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA.

  2014cited by this paper
• Implementing precision medicine initiatives in the clinic: a new paradigm in drug development

  2014cited by this paper
• A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

  2014cited by this paper
• Genetics of hepatocellular carcinoma: the next generation.

  2014cited by this paper
• Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.

  2014cited by this paper
• Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis

  2014cited by this paper
• Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.

  2014cited by this paper
• Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.

  2013cited by this paper
• Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

  2013cited by this paper
• Novel anticancer therapeutics targeting telomerase.

  2013cited by this paper
• Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

  2013cited by this paper
• Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

  2013cited by this paper
• Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma

  2013cited by this paper
• Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial).

  2013cited by this paper
• Cancer drug resistance: an evolving paradigm

  2013cited by this paper
• Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

  2013cited by this paper
• Designing transformative clinical trials in the cancer genome era.

  2013cited by this paper
• Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

  2013cited by this paper
• Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

  2013cited by this paper
• Abstract 4598: Identification of driver genes in hepatocellular carcinoma by exome sequencing.

  2013cited by this paper
• Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

  2013cited by this paper
• Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis.

  2013cited by this paper
• A phase I study of temsirolimus as novel therapeutic drug for patients with unresectable hepatocellular carcinoma (HCC).

  2013cited by this paper
• Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.

  2013cited by this paper
• Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

  2013cited by this paper
• A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

  2013cited by this paper
• Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

  2013cited by this paper
• Risk factors for the development of chemotherapy-related hospitalization (CRH) in patients treated with palliative intent: Results of a 9-year nested case control study.

  2013cited by this paper
• Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.

  2013cited by this paper
• Analysis of circulating tumor DNA to monitor metastatic breast cancer.

  2013cited by this paper
• Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

  2013cited by this paper
• Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).

  2013cited by this paper
• A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma

  2013cited by this paper
• A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

  2012cited by this paper
• Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial

  2012cited by this paper
• Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

  2012cited by this paper
• Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

  2012cited by this paper
• Lenalidomide in solid tumors

  2012cited by this paper
• Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib

  2012cited by this paper
• EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib

  2012cited by this paper
• Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.

  2012cited by this paper
• Cancer genomics: technology, discovery, and translation.

  2012cited by this paper
• Gemcitabine and Docetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial

  2012cited by this paper
• Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

  2012cited by this paper
• Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

  2012cited by this paper
• Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design

  2012cited by this paper
• Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.

  2012cited by this paper
• Activity of Cabozantinib (XL184) in Hepatocellular Carcinoma (HCC) Patients: Results From a Phase 2 Randomized Discontinuation Trial (RDT)

  2012cited by this paper
• Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.

  2012influential reference
• A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).

  2012cited by this paper
• A phase I/II study of AZD6244 in combination with sorafenib in advanced hepatocellular carcinoma.

  2012cited by this paper
• A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

  2012cited by this paper
• Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

  2012cited by this paper
• Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC)

  2012cited by this paper
• Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer

  2012cited by this paper
• A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC).

  2012cited by this paper
• Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing

  2011cited by this paper
• A phase I study of AVE1642, a human monoclonal antibody-blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC).

  2011cited by this paper
• Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

  2011influential reference
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

  2011cited by this paper
• Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.

  2011cited by this paper
• Potential of immunotherapy for hepatocellular carcinoma.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

  2011cited by this paper
• Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

  2011cited by this paper
• Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

  2011cited by this paper
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

  2010cited by this paper

• Global research trends and hotspots on environmental pollution and primary liver cancer: a bibliometric and visualized analysis

  2025cites this paper
• Irisin Amplifies the Apoptotic Effects of Gefitinib in HepG2 Cells

  2025cites this paper
• Exosome-mediated Crosstalk in the Tumor Immune Microenvironment: Critical Drivers of Hepatocellular Carcinoma Progression

  2024cites this paper
• Causal Effect of Immunocytes, Plasma Metabolites, and Hepatocellular Carcinoma: A Bidirectional Two-Sample Mendelian Randomization Study and Mediation Analysis in East Asian Populations

  2024cites this paper
• Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma.

  2024cites this paper
• Identification and validation of an H2AZ1-based index model: a novel prognostic tool for hepatocellular carcinoma

  2024cites this paper
• Six immune-related promising biomarkers may promote hepatocellular carcinoma prognosis: a bioinformatics analysis and experimental validation

  2023cites this paper
• Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles

  2023cites this paper
• Secular Trends of Liver Cancer Mortality and Years of Life Lost in Wuhan, China 2010–2019

  2023cites this paper
• Ultrasound targeted microbubble destruction-triggered nitric oxide release via nanoscale ultrasound contrast agent for sensitizing chemoimmunotherapy

  2023cites this paper
• Dual-targeting nanotheranostics for MRI-guided enhanced chemodynamic therapy of hepatoma via regulating the tumor microenvironment.

  2023cites this paper
• Exosome Cargos as Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma

  2023cites this paper
• Diagnostic accuracy of serum derived exosomes for hepatocellular carcinoma: a systematic review and meta-analysis

  2023cites this paper
• Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid‐derived suppressor cells in hepatocellular carcinoma

  2023cites this paper
• LATS‐regulated nuclear‐cytoplasmic translocation of SREBP2 inhibits hepatocellular carcinoma cell migration and invasion via epithelial–mesenchymal transition

  2023cites this paper
• Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p

  2022influential citation
• The prognosis and clinicopathological significance of histone deacetylase in hepatocellular carcinoma: a meta-analysis

  2022cites this paper
• Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma

  2022cites this paper
• Curcumin induces mitochondrial apoptosis in human hepatoma cells through BCLAF1-mediated modulation of PI3K/AKT/GSK-3β signaling.

  2022cites this paper
• Exosomes as potential diagnosis and treatment for liver cancer

  2022cites this paper
• Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma

  2021cites this paper
• RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC

  2021cites this paper
• Cyclin-dependent kinase 1 as a potential target for lycorine against hepatocellular carcinoma.

  2021cites this paper
• Identification of a Prognostic Index Based on a Metabolic-Genomic Landscape Analysis of Hepatocellular Carcinoma (HCC)

  2021cites this paper
• A Novel Five-Gene Signature for Prognosis Prediction in Hepatocellular Carcinoma

  2021cites this paper
• Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF‐kB signaling pathways synergistically

  2021cites this paper
• Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination

  2020cites this paper
• Expansile Nanoparticles Encapsulate Factor Quinolinone Inhibitor 1 and Accumulate in Murine Liver upon Intravenous Administration.

  2020cites this paper
• KCNQ 1 OT 1 contributes to sorafenib resistance and programmed death ‐ ligand ‐ 1 ‐ mediated immune escape via sponging miR ‐ 506 in hepatocellular carcinoma cells

  2020cites this paper
• KCNQ1OT1 contributes to sorafenib resistance and programmed death-ligand-1-mediated immune escape via sponging miR-506 in hepatocellular carcinoma cells

  2020cites this paper
• Construction prognosis model based on autophagy-related gene signatures in hepatocellular carcinoma.

  2020cites this paper
• A study on the effects of tumor-derived exosomes on hepatoma cells and hepatocytes by atomic force microscopy.

  2020cites this paper
• Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway‐related proteins

  2020cites this paper
• Identi�cation of Prognostic Genes Associated with Expression Differentiation During Metabolism Process in Hepatocellular Carcinoma (HCC)

  2020cites this paper
• Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

  2019cites this paper
• MiR-129-5p inhibits liver cancer growth by targeting calcium calmodulin-dependent protein kinase IV (CAMK4)

  2019cites this paper
• Systemic treatment of advanced hepatocellular cancer: new hope on the horizon

  2019cites this paper
• Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens.

  2019cites this paper
• Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer

  2019cites this paper
• Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line

  2019cites this paper
• Study of serum level of vascular endothelial growth factor in patients with hepatocellular carcinoma

  2019cites this paper
• Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib

  2019cites this paper
• The comparative safety and efficacy of S-1 versus the best supportive care in advanced hepatocellular carcinoma

  2019cites this paper
• LncRNA MAGI2‐AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR‐374b‐5p/SMG1 signaling pathway

  2019cites this paper
• Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system

  2018cites this paper
• Systemic treatment for hepatocellular carcinoma: Still unmet expectations

  2017cites this paper
• Multiple roles of glyoxalase 1-mediated suppression of methylglyoxal glycation in cancer biology-Involvement in tumour suppression, tumour growth, multidrug resistance and target for chemotherapy.

  2017cites this paper
• Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4

  2017cites this paper
• Oncogenic Secretory Clusterin: A Promising Therapeutic Target for Hepatocellular Carcinoma

  2017cites this paper
• In vitro Anti-Proliferative Effect of Tephrosia purpurea on Human Hepatocellular Carcinoma Cells

  2017cites this paper
• Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target.

  2017cites this paper
• Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.

  2017cites this paper
• Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma

  2017cites this paper
• Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).

  2016cites this paper
• Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

  2016cites this paper
• Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo

  2016cites this paper
• Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target

  2016cites this paper
• Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.

  2016cites this paper
• Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells

  2016cites this paper
• MiR-1180 promoted the proliferation of hepatocellular carcinoma cells by repressing TNIP2 expression.

  2016cites this paper
• Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib.

  2016cites this paper
• Challenges of advanced hepatocellular carcinoma

  2016cites this paper
• Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy

  2016cites this paper
• Tumor-targeted docetaxel-loaded hyaluronic acid-quercetin polymeric micelles with p-gp inhibitory property for hepatic cancer therapy

  2016cites this paper
• Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis

  2015cites this paper
• Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.

  2015cites this paper
• [Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].

  2015cites this paper
• DOTTORATO DI RICERCA IN “Scienze Cliniche”

  2015cites this paper
• Systemic Chemotherapy in Orthotopic Liver Transplantation

  2015cites this paper
• Causal effect between immunocytes, plasma metabolites, and hepatocellular carcinoma: a bidirectional two-sample Mendelian randomization study and mediation analysis

  year unknowncites this paper
• A Novel Differentially Expressed Cuproptosis-Related lncRNAs Signature to predict the prognosis and immune characteristics of hepatocellular carcinoma

  year unknowncites this paper